Reducing Anticoagulation Duration for Children After a Provoked Deep Venous Thrombosis

References

1. 1.↵
   1. Goldenberg NA,
   2. Kittelson JM,
   3. Abshire TC,
   4. Abshire TC

   , Kids-DOTT Trial Investigators and the ATLAS Group, et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT Randomized Clinical Trial. JAMA 2022;327:129–37.
2. 2.↵
   1. Ebell MH,
   2. Siwek J,
   3. Weiss BD,
   4. et al

   . Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17(1):59–67.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Stein PD,
   2. Kayali F,
   3. Olson RE

   . Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr 2004;145:563–5.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. White RH

   . The epidemiology of venous thromboembolism. Circulation 2003;107:14–8.

   OpenUrlCrossRef
5. 5.↵
   1. Kearon C,
   2. Akl EA,
   3. Ornelas J,
   4. et al

   . Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. Feb 2016;149:315–52.

   OpenUrl
6. 6.↵
   1. Monagle P,
   2. Cuello CA,
   3. Augustine C,
   4. et al

   . American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018;2:3292–316.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Schulman S,
   2. Rhedin AS,
   3. Lindmarker P,
   4. et al

   . A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–5.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Monagle P,
   2. Chalmers E,
   3. Chan A,
   4. et al

   . Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest Suppl 2008;133:887s–968s.

   OpenUrl
9. 9.↵
   1. Smith P,
   2. Castelli G

   . The priority updates from the research literature (PURLs) methodology. J Am Board Fam Med 2024;37:799–802.

   OpenUrlFREE Full Text
10. 10.↵
    1. Male C,
    2. Lensing AWA,
    3. Palumbo JS

    , EINSTEIN-Jr Phase 3 Investigatorset al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020;7:e18–e27.

    OpenUrl
11. 11.↵
    1. Halton J,
    2. Brandão LR,
    3. Luciani M

    , DIVERSITY Trial Investigatorset al. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021;8:e22–e33.

    OpenUrlPubMed